Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this trial is to estimate the therapeutic efficacy of the experimental targeted regimen including the EGFR antibody panitumumab (in combination with pemetrexed and cisplatin) in relation to the standard combination in patients with a KRAS wild-type stage IIIB or IV primary nonsquamous non-small cell lung cancer. It is expected that the progression free survival rate at 6 months is improved by the targeted regimen.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Histologically confirmed diagnosis of inoperable stage IIIB or IV primary pulmonary nonsquamous NSCLC (according to UICC staging valid until 2008)
Sufficient representative sample material for KRAS analysis
Wild-type KRAS
Informed consent of the patient
Aged at least 18 years
WHO Performance Status 0-2
At least one unidimensional, measurable tumour parameter according to RECIST
Life expectancy of al least 12 weeks
Adequate haematological, hepatic, renal and metabolic function parameters:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
134 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal